{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T03:19:36Z","timestamp":1794367176014,"version":"4.9.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T00:00:00Z","timestamp":1519603200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1038\/s41386-018-0028-6","type":"journal-article","created":{"date-parts":[[2018,2,26]],"date-time":"2018-02-26T22:25:29Z","timestamp":1519683929000},"page":"1667-1674","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Cell-subtype-specific changes in adenosine pathways in schizophrenia"],"prefix":"10.1038","volume":"43","author":[{"given":"Sinead Marie","family":"O\u2019Donovan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Koene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Hasselfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassidy Lynn","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Erne","family":"McCullumsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,2,26]]},"reference":[{"key":"28_CR1","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMra035458","volume":"349","author":"R Freedman","year":"2003","unstructured":"Freedman R. Schizophrenia. N Engl J Med. 2003;349:1738\u201349.","journal-title":"N Engl J Med"},{"key":"28_CR2","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","volume":"374","author":"J Os van","year":"2009","unstructured":"van Os J, Kapur S. Schizophrenia. Lancet. 2009;374:635\u201345.","journal-title":"Lancet"},{"key":"28_CR3","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1001\/archpsyc.1982.04290090001001","volume":"39","author":"AV Mackay","year":"1982","unstructured":"Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry. 1982;39:991\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"28_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/S0022-3956(99)00029-1","volume":"33","author":"JW Olney","year":"1999","unstructured":"Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33:523\u201333.","journal-title":"J Psychiatr Res"},{"key":"28_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.pnpbp.2006.02.002","volume":"30","author":"DR Lara","year":"2006","unstructured":"Lara DR, Dall\u2019Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:617\u201329.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"28_CR6","doi-asserted-by":"publisher","first-page":"909","DOI":"10.2174\/156802611795347555","volume":"11","author":"PL Ipata","year":"2011","unstructured":"Ipata PL, Camici M, Micheli V, Tozz MG. Metabolic network of nucleosides in the brain. Curr Top Med Chem. 2011;11:909\u201322.","journal-title":"Curr Top Med Chem"},{"key":"28_CR7","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/jnc.13724","volume":"139","author":"RA Cunha","year":"2016","unstructured":"Cunha RA. How does adenosine control neuronal dysfunction and neurodegeneration? J Neurochem. 2016;139:1019\u201355.","journal-title":"J Neurochem"},{"key":"28_CR8","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.1111\/j.1460-9568.2007.05897.x","volume":"26","author":"BK Yee","year":"2007","unstructured":"Yee BK, Singer P, Chen JF, Feldon J, Boison D. Transgenic overexpression of adenosine kinase in brain leads to multiple learning impairments and altered sensitivity to psychomimetic drugs. Eur J Neurosci. 2007;26:3237\u201352.","journal-title":"Eur J Neurosci"},{"key":"28_CR9","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1016\/j.neuropharm.2011.01.048","volume":"62","author":"D Boison","year":"2012","unstructured":"Boison D, Singer P, Shen HY, Feldon J, Yee BK. Adenosine hypothesis of schizophrenia\u2013opportunities for pharmacotherapy. Neuropharmacology. 2012;62:1527\u201343.","journal-title":"Neuropharmacology"},{"key":"28_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1124\/pr.112.006361","volume":"65","author":"D Boison","year":"2013","unstructured":"Boison D. Adenosine kinase: exploitation for therapeutic gain. Pharmacol Rev. 2013;65:906\u201343.","journal-title":"Pharmacol Rev"},{"key":"28_CR11","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/cdd.2009.131","volume":"17","author":"D Boison","year":"2010","unstructured":"Boison D, Chen JF, Fredholm BB. Adenosine signaling and function in glial cells. Cell Death Differ. 2010;17:1071\u201382.","journal-title":"Cell Death Differ"},{"key":"28_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4088\/JCP.v66n0209","volume":"66","author":"MG Brunstein","year":"2005","unstructured":"Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry. 2005;66:213\u20139.","journal-title":"J Clin Psychiatry"},{"key":"28_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2013.94","volume":"3","author":"Y Hwang","year":"2013","unstructured":"Hwang Y, Kim J, Shin JY, Kim JI, Seo JS, Webster MJ, et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune\/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry. 2013;3:e321.","journal-title":"Transl Psychiatry"},{"key":"28_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/00001756-200303030-00003","volume":"14","author":"J Deckert","year":"2003","unstructured":"Deckert J, Brenner M, Durany N, Zochling R, Paulus W, Ransmayr G, et al. Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport. 2003;14:313\u20136.","journal-title":"Neuroreport"},{"key":"28_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0006-8993(98)00840-3","volume":"808","author":"A Kurumaji","year":"1998","unstructured":"Kurumaji A, Toru M. An increase in [3H] CGS21680 binding in the striatum of postmortem brains of chronic schizophrenics. Brain Res. 1998;808:320\u20133.","journal-title":"Brain Res"},{"key":"28_CR16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jpsychires.2013.12.013","volume":"51","author":"I Villar-Menendez","year":"2014","unstructured":"Villar-Menendez I, Diaz-Sanchez S, Blanch M, Albasanz JL, Pereira-Veiga T, Monje A, et al. Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. J Psychiatr Res. 2014;51:49\u201359.","journal-title":"J Psychiatr Res"},{"key":"28_CR17","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s11302-013-9370-7","volume":"9","author":"E Aliagas","year":"2013","unstructured":"Aliagas E, Villar-Menendez I, Sevigny J, Roca M, Romeu M, Ferrer I, et al. Reduced striatal ecto-nucleotidase activity in schizophrenia patients supports the \u201cadenosine hypothesis\u201d. Purinergic Signal. 2013;9:599\u2013608.","journal-title":"Purinergic Signal"},{"key":"28_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1126\/science.1116916","volume":"310","author":"O Pascual","year":"2005","unstructured":"Pascual O, Casper KB, Kubera C, Zhang J, Revilla-Sanchez R, Sul JY, et al. Astrocytic purinergic signaling coordinates synaptic networks. Science. 2005;310:113\u20136.","journal-title":"Science"},{"key":"28_CR19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.neuint.2007.06.026","volume":"52","author":"RA Cunha","year":"2008","unstructured":"Cunha RA. Different cellular sources and different roles of adenosine: A1 receptor-mediated inhibition through astrocytic-driven volume transmission and synapse-restricted A2A receptor-mediated facilitation of plasticity. Neurochem Int. 2008;52:65\u201372.","journal-title":"Neurochem Int"},{"key":"28_CR20","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1471-4159.2001.00607.x","volume":"79","author":"S Latini","year":"2001","unstructured":"Latini S, Pedata F. Adenosine in the central nervous system: release mechanisms and extracellular concentrations. J Neurochem. 2001;79:463\u201384.","journal-title":"J Neurochem"},{"key":"28_CR21","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1097\/00001756-199809140-00016","volume":"9","author":"JM Brundege","year":"1998","unstructured":"Brundege JM, Dunwiddie TV. Metabolic regulation of endogenous adenosine release from single neurons. Neuroreport. 1998;9:3007\u201311.","journal-title":"Neuroreport"},{"key":"28_CR22","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1523\/JNEUROSCI.6052-11.2012","volume":"32","author":"BP Klyuch","year":"2012","unstructured":"Klyuch BP, Dale N, Wall MJ. Deletion of ecto-5\u2019-nucleotidase (CD73) reveals direct action potential-dependent adenosine release. J Neurosci: Off J Soc Neurosci. 2012;32:3842\u20137.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"28_CR23","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.1073\/pnas.1120997109","volume":"109","author":"D Lovatt","year":"2012","unstructured":"Lovatt D, Xu Q, Liu W, Takano T, Smith NA, Schnermann J, et al. Neuronal adenosine release, and not astrocytic ATP release, mediates feedback inhibition of excitatory activity. Proc Natl Acad Sci USA. 2012;109:6265\u201370.","journal-title":"Proc Natl Acad Sci USA"},{"key":"28_CR24","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/mp.2015.148","volume":"21","author":"RE McCullumsmith","year":"2016","unstructured":"McCullumsmith RE, O\u2019Donovan SM, Drummond JB, Benesh FS, Simmons M, Roberts R, et al. Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons? Mol Psychiatry. 2016;21:823\u201330.","journal-title":"Mol Psychiatry"},{"key":"28_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.74","volume":"5","author":"SM O\u2019Donovan","year":"2015","unstructured":"O\u2019Donovan SM, Hasselfeld K, Bauer D, Simmons M, Roussos P, Haroutunian V, et al. Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia. Transl Psychiatry. 2015;5:e579.","journal-title":"Transl Psychiatry"},{"key":"28_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.biopsych.2011.02.022","volume":"70","author":"MS Sodhi","year":"2011","unstructured":"Sodhi MS, Simmons M, McCullumsmith R, Haroutunian V, Meador-Woodruff JH. Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry. 2011;70:646\u201354.","journal-title":"Biol Psychiatry"},{"key":"28_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.schres.2013.03.010","volume":"147","author":"JB Drummond","year":"2013","unstructured":"Drummond JB, Tucholski J, Haroutunian V, Meador-Woodruff JH. Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in anterior cingulate cortex in schizophrenia. Schizophr Res. 2013;147:32\u20138.","journal-title":"Schizophr Res"},{"key":"28_CR28","first-page":"275","volume":"6","author":"K Kashihara","year":"1986","unstructured":"Kashihara K, Sato M, Fujiwara Y, Ogawa T, Fukuda K, Otsuki S. Effects of intermittent and continuous haloperidol administration on the dopaminergic system in the rat brain. Yakubutsu Seishin Kodo\u2009=\u2009Japanese J Psychopharmacol. 1986;6:275\u201380.","journal-title":"Yakubutsu Seishin Kodo\u2009=\u2009Japanese J Psychopharmacol"},{"key":"28_CR29","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11302-012-9309-4","volume":"8","author":"H Zimmermann","year":"2012","unstructured":"Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012;8:437\u2013502.","journal-title":"Purinergic Signal"},{"key":"28_CR30","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.bbamcr.2008.01.024","volume":"1783","author":"GG Yegutkin","year":"2008","unstructured":"Yegutkin GG. Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta. 2008;1783:673\u201394.","journal-title":"Biochim Biophys Acta"},{"key":"28_CR31","doi-asserted-by":"publisher","first-page":"re1","DOI":"10.1126\/scisignal.3104re1","volume":"3","author":"R Corriden","year":"2010","unstructured":"Corriden R, Insel PA. Basal release of ATP: an autocrine-paracrine mechanism for cell regulation. Sci Signal. 2010;3:re1.","journal-title":"Sci Signal"},{"key":"28_CR32","doi-asserted-by":"publisher","first-page":"19040","DOI":"10.1074\/jbc.M113.466102","volume":"288","author":"D Lu","year":"2013","unstructured":"Lu D, Insel PA. Hydrolysis of extracellular ATP by ectonucleoside triphosphate diphosphohydrolase (ENTPD) establishes the set point for fibrotic activity of cardiac fibroblasts. J Biol Chem. 2013;288:19040\u20139.","journal-title":"J Biol Chem"},{"key":"28_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1146\/annurev.neuro.24.1.31","volume":"24","author":"TV Dunwiddie","year":"2001","unstructured":"Dunwiddie TV, Masino SA. The role and regulation of adenosine in the central nervous system. Annu Rev Neurosci. 2001;24:31\u201355.","journal-title":"Annu Rev Neurosci"},{"key":"28_CR34","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nn1288","volume":"7","author":"DS Choi","year":"2004","unstructured":"Choi DS, Cascini MG, Mailliard W, Young H, Paredes P, McMahon T, et al. The type 1 equilibrative nucleoside transporter regulates ethanol intoxication and preference. Nat Neurosci. 2004;7:855\u201361.","journal-title":"Nat Neurosci"},{"key":"28_CR35","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/WNR.0b013e3283500987","volume":"23","author":"D Shan","year":"2012","unstructured":"Shan D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE. Expression of equilibrative nucleoside transporter type 1 protein in elderly patients with schizophrenia. Neuroreport. 2012a;23:224\u20137.","journal-title":"Neuroreport"},{"key":"28_CR36","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1113\/jphysiol.2013.253450","volume":"591","author":"MJ Wall","year":"2013","unstructured":"Wall MJ, Dale N. Neuronal transporter and astrocytic ATP exocytosis underlie activity-dependent adenosine release in the hippocampus. J Physiol. 2013;591:3853\u201371.","journal-title":"J Physiol"},{"key":"28_CR37","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/1098-1128(200103)21:2<105::AID-MED1002>3.0.CO;2-U","volume":"21","author":"G Cristalli","year":"2001","unstructured":"Cristalli G, Costanzi S, Lambertucci C, Lupidi G, Vittori S, Volpini R, et al. Adenosine deaminase: functional implications and different classes of inhibitors. Med Res Rev. 2001;21:105\u201328.","journal-title":"Med Res Rev"},{"key":"28_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.neulet.2006.11.071","volume":"414","author":"MG Brunstein","year":"2007","unstructured":"Brunstein MG, Silveira EM Jr., Chaves LS, Machado H, Schenkel O, Belmonte-de-Abreu P, et al. Increased serum adenosine deaminase activity in schizophrenic receiving antipsychotic treatment. Neurosci Lett. 2007;414:61\u20134.","journal-title":"Neurosci Lett"},{"key":"28_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1590\/S1516-44462010005000003","volume":"32","author":"GP Dutra","year":"2010","unstructured":"Dutra GP, Ottoni GL, Lara DR, Bogo MR. Lower frequency of the low activity adenosine deaminase allelic variant (ADA1*2) in schizophrenic patients. Rev Bras De Psiquiatr. 2010;32:275\u20138.","journal-title":"Rev Bras De Psiquiatr"},{"key":"28_CR40","first-page":"233","volume":"53","author":"D Shan","year":"2012","unstructured":"Shan D, Yates S, Roberts RC, McCullumsmith RE. Update on the neurobiology of schizophrenia: a role for extracellular microdomains. Minerva Psichiatr. 2012b;53:233\u201349.","journal-title":"Minerva Psichiatr"},{"key":"28_CR41","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0074-7742(05)63007-3","volume":"63","author":"BB Fredholm","year":"2005","unstructured":"Fredholm BB, Chen JF, Cunha RA, Svenningsson P, Vaugeois JM. Adenosine and brain function. Int Rev Neurobiol. 2005;63:191\u2013270.","journal-title":"Int Rev Neurobiol"},{"key":"28_CR42","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1046\/j.1460-9568.2002.02122.x","volume":"16","author":"L Gimenez-Llort","year":"2002","unstructured":"Gimenez-Llort L, Fernandez-Teruel A, Escorihuela RM, Fredholm BB, Tobena A, Pekny M, et al. Mice lacking the adenosine A1 receptor are anxious and aggressive, but are normal learners with reduced muscle strength and survival rate. Eur J Neurosci. 2002;16:547\u201350.","journal-title":"Eur J Neurosci"},{"key":"28_CR43","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/npp.2014.337","volume":"40","author":"RE McCullumsmith","year":"2015","unstructured":"McCullumsmith RE, Hammond JH, Shan D, Meador-Woodruff JH. Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol. 2015;40:1307.","journal-title":"Neuropsychopharmacol: Off Publ Am Coll Neuropsychopharmacol"},{"key":"28_CR44","doi-asserted-by":"publisher","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","volume":"34","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O\u2019Keeffe S, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci: Off J Soc Neurosci. 2014;34:11929\u201347.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"28_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10695-015-0093-2","volume":"41","author":"KJ Seibt","year":"2015","unstructured":"Seibt KJ, Oliveira Rda L, Bogo MR, Senger MR, Bonan CD. Investigation into effects of antipsychotics on ectonucleotidase and adenosine deaminase in zebrafish brain. Fish Physiol Biochem. 2015;41:1383\u201392.","journal-title":"Fish Physiol Biochem"},{"key":"28_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.tiv.2008.10.003","volume":"23","author":"KJ Seibt","year":"2009","unstructured":"Seibt KJ, Oliveira Rda L, Rico EP, Dias RD, Bogo MR, Bonan CD. Antipsychotic drugs inhibit nucleotide hydrolysis in zebrafish (Danio rerio) brain membranes. Toxicol Vitr: Int J Publ Assoc BIBRA. 2009;23:78\u201382.","journal-title":"Toxicol Vitr: Int J Publ Assoc BIBRA"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0028-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-018-0028-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:02:22Z","timestamp":1684616542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-018-0028-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,26]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1038\/s41386-018-0028-6","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,26]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}